KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Herpes Simplex Encephalitis: Flair axial MRIs. Note the abnormal (bright) signal in both temporal lobes (left image). Also note the involvement of the insula on the right side (middle image) and the ...
Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...
Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback